Posted On: 01/04/2015 11:11:38 AM
Post# of 30066
would agree with you on the premise that LymPro is aiming to be the 1st to market, which would also promulgate LymPro's designation as a proprietary product
http://globenewswire.com/news-release/2014/10...J5RS7.dpuf
- IMHO any successful product 1st to market such as LymPro will have huge monetary rewards for shareholders
- AMBS most assuredly has the brain trust and ICON BP connection prowess to own the blood based bio-marker assay landscape for multiple of years, without undue competition from 'others'
- question is (licensing aside as a seperate profit center), do you accept a LymPro JV Agreement now and encumber the asset, or do you hold off until spin-off
Quote:
"Amarantus is aiming to be first to market with an accurate, reliable and commercially viable diagnostic blood test for Alzheimer's disease"
http://globenewswire.com/news-release/2014/10...J5RS7.dpuf
- IMHO any successful product 1st to market such as LymPro will have huge monetary rewards for shareholders
- AMBS most assuredly has the brain trust and ICON BP connection prowess to own the blood based bio-marker assay landscape for multiple of years, without undue competition from 'others'
- question is (licensing aside as a seperate profit center), do you accept a LymPro JV Agreement now and encumber the asset, or do you hold off until spin-off
(0)
(0)
